Riskpilot← Back to searchSign inGet full accessE. Urologyreal AB
ABActiveOrg 5590699434Björklundavägen 24 Lgh 1204Hospital activities · NACE 8610Est. 20161 employees
Revenue 2025
SEK 575K
-15% vs 2024
EBITDA margin
60.7%
+2% vs 2024
Equity ratio
44.0%
Financial strength
Net profit 2025
SEK 220K
-12% vs 2024
| Revenue | SEK 575K | -15% |
| EBITDA | SEK 349K | +2% |
| Net profit | SEK 220K | -12% |
| Total assets | SEK 1,2M | -10% |
| Equity | SEK 533K | -9% |
| Employees | 1 | — |
Legal name
E. Urologyreal AB
Org number
5590699434
Legal form
Aktiebolag
NACE code
8610 · Hospital activities
Founded
12 juli 2016
Share capital
SEK 50 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-06-30
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget ska bedriva konsultuppdrag med medicinsk konsultation, förvaltning av aktier och andra värdepapper samt därmed förenliga verksamheter. Handel med fastighet för bland annat medicinsk bruk med därtill hörande upprustning och inredning. Handel med medicinsk teknisk utrustning samt hjälpmedel, produkter och läkemedel.
Address
Björklundavägen 24 Lgh 1204
Email
emadsabir68@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 222 | 269 | 1 115 | 678 | 575 |
| Staff expenses | — | −75 | −132 | −165 | −129 |
| EBITDA | 19 | 121 | 851 | 341 | 349 |
| Depreciation & amort. | −0 | — | — | — | — |
| EBIT | 19 | 121 | 851 | 341 | 349 |
| Net financials | — | — | 0 | 1 | −6 |
| Profit before tax | 19 | 121 | 708 | 323 | 285 |
| Tax | −6 | −27 | −151 | −73 | −66 |
| Net profit | 13 | 94 | 557 | 250 | 220 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 514 | 624 | 1 407 | 1 343 | 1 212 |
| Equity | 214 | 308 | 608 | 588 | 533 |
| Long-term debt | 0 | — | — | — | — |
| Short-term debt | 57 | 73 | 412 | 350 | 217 |
| Total debt | 57 | 73 | 412 | 350 | 217 |
EBITDA margin
60.7%
This company
15.8%
Market median
+284% vs market
20212025
Equity ratio
44.0%
This company
38.2%
Market median
+15% vs market
20212025
Return on equity
41.2%
This company
18.4%
Market median
+124% vs market
20212025
Net profit margin
38.2%
This company
8.1%
Market median
+372% vs market
20212025
Asset turnover
0.47×
This company
1.12×
Market median
-58% vs market
20212025
Debt / equity
1.28×
This company
0.62×
Market median
-106% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-07-01 – 2025-06-30
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-07-01 – 2024-06-30
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-07-01 – 2023-06-30
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-07-01 – 2022-06-30
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-07-01 – 2021-06-30
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2022 | |
| Deputy Board Member | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of E. Urologyreal AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Emad Fadhel Sabir | Board of Directors | 0 companies |
| Sarah Nejdet Hamid | Deputy Board Member | 0 companies |